Safety and efficacy of Formoterol Fumarate + Fluticasone propionate in Indian asthmatic patients.

Background: Asthma is characterized by a chronic airway inûammation that may lead to airway obstruction, hyperresponsiveness, and clinical symptoms of cough, wheeze, and shortness of breath. Current asthma management guidelines recommend the use of this combination of LABA + ICS for patients who remain symptomatic on low-dose inhaled corticosteroids. Objective: This study was conducted to evaluate the efficacy and safety of the fixed dose combination of formoterol and fluticasone in clinical practice. Method: It was an open - labeled surveillance study enrolling 110 patients of asthma not adequately controlled on ICS alone. Results: At the end of 4 week of treatment with MDI and DPI of the fixed dose combination of Formoterol and Fluticasone, study population reported a significant reduction of mean cough score by 87.9% form baseline (Baseline 2.31 Vs 0.28 at 4 week). Similarly, the mean scores for wheeze and tightness of chest reduced to 0 form baseline (a reduction of 100%). The mean score of shortness of breath also showed a significant reduction of 89.6% at the end of study period form baseline. Conclusion: A fixed dose combination of formoterol + fluticasone MDI/DPI is safe and efficacious in the management of asthmatic patients not adequately controlled on inhalational corticosteroids alone in clinical practice in India. [ABSTRACT FROM AUTHOR]

Copyright of Indian Journal of Public Health Research & Development is the property of Institute of Medico-legal publications Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)